[1]何宗阳,陈赛男,包志瑶,等.桑麻杏贝汤对慢性阻塞性肺疾病模型大鼠炎症因子及肺功能作用机制研究[J].陕西中医,2024,(10):1315-1319.[doi:DOI:10.3969/j.issn.1000-7369.2024.10.004]
　HE Zongyang,CHEN Sainan,BAO Zhiyao,et al.Mechanism of Sangma Xingbei decoction in intervention of inflammatory factors and pulmonary function in rats with chronic obstructive pulmonary disease[J].,2024,(10):1315-1319.[doi:DOI:10.3969/j.issn.1000-7369.2024.10.004]
点击复制

桑麻杏贝汤对慢性阻塞性肺疾病模型大鼠炎症因子及肺功能作用机制研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年10期
页码:
1315-1319
栏目:
基础研究
出版日期:
2024-10-05

文章信息/Info

Title:
Mechanism of Sangma Xingbei decoction in intervention of inflammatory factors and pulmonary function in rats with chronic obstructive pulmonary disease
作者:
何宗阳1; 陈赛男1; 包志瑶2; 陈金涛1; 许 玲1; 季思勤1; 何新慧3; 王振伟1
(1.上海中医药大学附属岳阳中西医结合医院,上海 200437; 2.上海交通大学医学院附属瑞金医院,上海 200025; 3.上海中医药大学,上海 201203)
Author(s):
HE Zongyang; CHEN Sainan; BAO Zhiyao; CHEN Jintao; XU Ling; JI Siqin; HE Xinhui; WANG Zhenwei
(Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200437,China)
关键词:
慢性阻塞性肺疾病;  桑麻杏贝汤;  大鼠;  用力肺活量;  肿瘤坏死因子-α;  白细胞介素-6;  炎性因子
Keywords:
Chronic obstructive pulmonary disease;  Sangma Xingbei decoction;  Rats;  Forced vital capacity;  Tumor necrosis factor-α;  Interleukin-6;  Inflammatory factors
分类号:
R 563
DOI:
DOI:10.3969/j.issn.1000-7369.2024.10.004
文献标志码:
A
摘要:
目的:探讨桑麻杏贝汤对慢性阻塞性肺疾病(COPD)模型大鼠炎症因子的影响及肺功能的改善作用。方法:将36只SPF级SD大鼠随机分为对照组、模型组和治疗组,每组各12只(雌雄各半),除对照组外,其余两组应用烟熏法构建COPD大鼠模型。治疗组予桑麻杏贝汤12 g/(kg·d)灌胃,模型组和对照组采用10 ml/(kg·d)0.9%氯化钠溶液灌胃。14 d干预结束后,测定大鼠用力肺活量(FVC)、0.1 s用力呼气容积(FEV0.1)、呼气峰值流速(PEF),采用酶联免疫吸附法检测大鼠血清中肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)的浓度水平,并应用HE染色法观察大鼠肺组织病理学变化。结果:与对照组相比,COPD模型组大鼠的FVC、PEF值均下降(P<0.05),血清TNF-α、IL-6、IL-8浓度水平均升高(P<0.01),肺组织病理变化加重。与模型组相比,桑麻杏贝汤组大鼠肺功能明显得到改善(P<0.05),血清炎症因子水平明显降低(P<0.05)。结论:桑麻杏贝汤能够改善COPD模型大鼠的肺功能等症状,其机制可能与下调TNF-α、IL-6、IL-8等炎症因子浓度水平,减少肺组织病理损伤密切相关。
Abstract:
Objective:To explore the effects of Sangma Xingbei decoction on inflammatory factors and pulmonary function and in rats with chronic obstructive pulmonary disease(COPD).Methods:A total of 36 SPF SD rats were divided into normal group,model group and treatment group randomly,with 12 rats in each group(half of male and half of female).Except for the normal group,the other two groups were used to construct COPD model by using cigarette smoke method.The treatment group was given 12 g/(kg·d)of Sangma Xingbei decoction by gavage,and the model group and normal group were given 10 ml/(kg·d)physiological saline by gavage.After 14 days' intervention,the pulmonary function(FVC,FEV0.1,PEF)of the rats was measured,the concentration levels of TNF-α,IL-6 and IL-8 in serum were detected by ELISA and the pathological changes of lung tissue were observed by HE staining.Results:Compared with the normal group,the pulmonary function of model group decreased(P<0.05),and the inflammatory factors(TNF-α,IL-6,and IL-8)increased(P<0.01).The pathological changes of lung tissue were significant.Compared with the model group,the pulmonary function of model group increased(P<0.05),and the inflammatory factors(TNF-α,IL-6,and IL-8)decreased(P<0.05).Conclusion:Sangma Xingbei decoction can effectively improve pulmonary function and its mechanism may be related to down-regulating the concentration levels of inflammatory factors such as TNF-α,IL-6,and IL-8 and preventing the lung tissue from being further destroyed.

参考文献/References:

[1] CELLI B,FABBRI L,CRINER G,et al.Definition and nomenclature of chronic obstructive pulmonary disease:Time for its revision[J].American Journal of Respiratory and Critical Care Medicine,2022,206(11):1317-1325.
[2] 陈典,隆寰宇,李姝润,等.2024年GOLD慢性阻塞性肺疾病诊断、治疗、管理及预防全球策略更新要点解读[J].中国全科医学,2024,27(13):1533-1543,1567.
[3] AGUSTI A,CELLI B R,CRINER G J,et al.Global initiative for chronic obstructive lung disease 2023 report:GOLD executive summary[J].The European Respiratory Journal,2023,61(4):2300239.
[4] 曾德优,张六一,肖创,等.慢性阻塞性肺疾病动物模型研究进展[J].陕西医学杂志,2022,51(4):507-510.
[5] 姚亮,张元雯,王心悦,等.何新慧治疗肺系疾病经验介绍[J].山西中医,2017,33(8):6-7.
[6] 姚亮,李佳怡,沈圆圆,等.何氏桑麻杏贝汤对慢性阻塞性肺疾病急性加重期影响的临床观察[J].上海中医药杂志,2018,52(2):51-54.
[7] 张婷,林也,陈小娟,等.慢性阻塞性肺疾病病证结合动物模型研究进展[J].中国中医急症,2021,30(12):2240-2244.
[8] 彭青和,李泽庚,刘向国,等.慢性阻塞性肺疾病动物模型建立研究进展[J].辽宁中医药大学学报,2013,15(9):116-119.
[9] UPADHYAY P,WU C W,PHAM A,et al.Animal models and mechanisms of tobacco smoke-induced chronic obstructive pulmonary disease(COPD)[J].Journal of Toxicology and Environmental Health,2023,26(5):275-305.
[10] 慢性阻塞性肺疾病中西医结合管理专家共识写作组,何权瀛,冯淬灵.慢性阻塞性肺疾病中西医结合管理专家共识(2023版)[J].中国全科医学,2023,26(35):4359-4371.
[11] BAI T,GUO J,DENG Y,et al.A systematical strategy for quality markers screening of different methods processing platycodonis radix based on phytochemical analysis and the impact on chronic obstructive pulmonary disease[J].Journal of Ethnopharmacology,2024,319(2):117311.
[12] 向杰,杨峰,李强,等.小柴胡汤加味治疗慢性阻塞性肺疾病急性加重期疗效及对患者细胞免疫状态的影响[J].陕西中医,2023,44(5):591-594.
[13] 王伟,足巴措,张旭.补肺汤治疗慢性阻塞性肺疾病急性加重期疗效及对患者Th1/Th2漂移的影响[J].陕西中医,2023,44(8):1078-1081.
[14] 刘敬敬,程玉峰,崔磊.化痰止咳平喘汤联合布地奈德治疗慢性阻塞性肺疾病急性加重期临床研究[J].陕西中医,2024,45(2):204-207.
[15] 吴文婷,李敏,蒲文娟.白藜芦醇对慢性阻塞性肺疾病大鼠 p38丝裂原活化蛋白激酶/核因子-κB信号通路的影响[J].陕西医学杂志,2023,52(11):1489-1492,1534.
[16] 于凌军,陈宪海.浅述慢性阻塞性肺疾病急性加重期中医病因病机研究[J].陕西中医学院学报,2013,36(3):117-118.
[17] 刘春芳,苏玉洁,徐亭亭,等.桑麻杏贝汤联合舒利迭治疗慢性阻塞性肺疾病临床研究[J].河南中医,2023,43(11):1690-1695.
[18] 刘春芳,曹会杰,李海燕,等.桑麻杏贝汤治疗慢性阻塞性肺疾病急性加重期痰热壅肺证60例[J].河南中医,2023,43(7):1062-1066.
[19] 盛家刚,季思勤,王振伟.桑麻杏贝汤结合补益宗气法针刺治疗慢性阻塞性肺疾病(稳定期)临床效果观察[J].辽宁中医杂志,2023,50(9):99-102.
[20] 韩慧,徐平,宋卫东.慢性阻塞性肺疾病患者气道炎症反应、肺功能与生化指标相关性研究[J].陕西医学杂志,2023,52(10):1358-1361,1366.
[21] 谢文英,尚立芝,胡文豪,等.慢性阻塞性肺疾病的发病机制及中医药治疗进展[J].中国实验方剂学杂志,2015,21(9):227-230.
[22] 国家卫生健康委员会急诊医学质控中心.中国慢性阻塞性肺疾病急性加重中西医诊治专家共识(2021)[J].中华危重病急救医学,2021,33(11):1281-1290.
[23] 白春昀,翁稚颖,肖创,等.慢性阻塞性肺病相关炎症细胞及因子的研究进展[J].慢性病学杂志,2019,20(1):42-46.
[24] 蔡东林,孙钟和,赵益庆.慢性阻塞性肺疾病稳定期BODE指数、IL-8、TNF-α水平与肺肾气虚证相关性研究[J].陕西中医,2020,41(11):1573-1575.
[25] 蔡蓉,宋琳,郭雪君.慢性阻塞性肺疾病急性加重期患者炎症因子的变化及意义[J].广西医学,2015,37(2):258-259.
[26] 张永,程德云,王慧,等.慢性阻塞性肺疾病大鼠肺内白细胞介素-8和肿瘤坏死因子-α与气道炎症的关系研究[J].中国呼吸与危重监护杂志,2003,11(6):39-43.
[27] 康睿,张亚琼.阿比多尔对慢性阻塞性肺疾病大鼠气道炎症及气道黏液高分泌影响的实验研究[J].陕西医学杂志,2022,51(4):391-395.
[28] 杜晓华,李为民.炎性因子在慢性阻塞性肺疾病急性加重期的作用研究[J].临床肺科杂志,2008,13(11):1399-1402.

相似文献/References:

[1]杨栓柱,王 文 △,李 猛,等.千金苇茎汤合瓜蒌薤白杏仁汤治疗 慢性阻塞性肺疾病急性加重期临床研究*[J].陕西中医,2019,(5):600.
[2]王 敏,陈 阁.清热化痰祛瘀方联合西药治疗慢性阻塞性肺疾病急性 加重期患者的临床研究[J].陕西中医,2019,(5):610.
　WANG Min,CHEN Ge..Clinical study of Qingre Huatan Quyu prescription combined with western medicine in the treatment of acute exacerbation of chronic obstructive pulmonary disease[J].,2019,(10):610.
[3]李天浩,韩晨旭,王惠琴,等.基于EGFR-MUC5AC信号通路探讨参鱼化痰口服液干预慢性阻塞性肺疾病大鼠气道黏液高分泌的机制*[J].陕西中医,2019,(8):995.
　LI Tianhao,HAN Chenxu,WANG Huiqin,et al.Based on EGFR-MUC5AC signaling pathway to explore the mechanism of Shenyu Huatan oral liquid in intervention of airway mucus high secretion in COPD rats[J].,2019,(10):995.
[4]王珊珊,谭光波△.补肺汤对慢性阻塞性肺疾病肺气肿大鼠血清IFNγ、IL4表达水平影响研究*[J].陕西中医,2019,(11):1491.
　WANG Shanshan,TAN Guangbo..Effect of Bufei decoction on the expression of IFNγ and IL4 in serum of rats with chronic obstructive pulmonary disease and emphysema[J].,2019,(10):1491.
[5]任英杰,王 起,陈秋生.黄芪汤加减治疗急性加重期慢性阻塞性肺疾病疗效研究[J].陕西中医,2020,(1):57.
　REN Yingjie,WANG Qi,CHEN Qiusheng..Observation on the curative effect of Huangqi decoction in the treatment ofacute exacerbation of chronic obstructive pulmonary disease[J].,2020,(10):57.
[6]聂清华,范伏元△.射干麻黄汤联合沙丁胺醇对慢性阻塞性肺疾病患者肺功能、生活质量的影响[J].陕西中医,2020,(2):180.
　NIE Qinghua,FAN Fuyuan..Effects of Shegan Mahuang decoction and albuterol on pulmonary function and quality of life in patients with COPD[J].,2020,(10):180.
[7]刘新平,王展儒.理肺化痰通脉方治疗慢性阻塞性肺疾病急性加重期临床研究[J].陕西中医,2020,(4):484.
[8]杜沂岚,唐 敏,陈朝晖△,等.经肺腧穴中药离子导入联合振动排痰治疗慢性阻塞性肺疾病急性加重期临床疗效*[J].陕西中医,2020,(4):534.
　DU Yilan,TANG Min,CHEN Zhaohui,et al.Clinical efficacy of Chinese medicine iontophoresis via Feishu point combined with vibration sputum discarding in the treatment of AECOPD[J].,2020,(10):534.
[9]唐颖丽,谢 珊,余清萍,等.子午流注法治疗慢性阻塞性肺疾病加重期痰浊阻肺证疗效研究*[J].陕西中医,2020,(9):1311.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.039]
　TANG Yingli,XIE Shan,YU Qingping,et al.Curative effect of midnight-noon ebb-flow method on chronic obstructive pulmonary disease exacerbation with syndrome of Tanzhuo Zufei[J].,2020,(10):1311.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.039]
[10]蔡东林,孙钟和,赵益庆.慢性阻塞性肺疾病稳定期BODE指数、IL-8、TNF-α水平与肺肾气虚证相关性研究*[J].陕西中医,2020,(11):1573.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.015]

备注/Memo

备注/Memo:
基金项目:上海市人才发展资金资助项目(2020088); 上海市虹口区“国医强优”三年行动计划项目(HKGYQYXM-2022-39); 上海市卫生健康委员会中医药科研项目(2020LP019)
更新日期/Last Update: 2024-10-08